Rune Kleppe

Rune Kleppe


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
EMElaheh Mahootchi
Elaheh Mahootchi
SHSelina Cannon Homaei
Selina Cannon Homaei
RKRune Kleppe
Rune Kleppe
IWIngeborg Winge
Ingeborg Winge
THTor-Arne Hegvik
Tor-Arne Hegvik
JHJan Haavik
Jan Haavik
Carnosine and related β-alanine–containing peptides are believed to be important antioxidants, pH buffers, and neuromodulators. However, their biosynthetic routes and therapeutic potential are still being debated. This study describes the first animal model lacking the enzyme glutamic acid decarboxylase–like 1 (GADL1). We show that Gadl1−/− mice are deficient in β-alanine, carnosine, and anserine, particularly in the olfactory bulb, cerebral cortex, and skeletal muscle. Gadl1−/− mice also exhibited decreased anxiety, increased levels of oxidative stress markers, alterations in energy and lipid metabolism, and age-related changes. Examination of the GADL1 active site indicated that the enzyme may have multiple physiological substrates, including aspartate and cysteine sulfinic acid. Human genetic studies show strong associations of the GADL1 locus with plasma levels of carnosine, subjective well-being, and muscle strength. Together, this shows the multifaceted and organ-specific roles of carnosine peptides and establishes Gadl1 knockout mice as a versatile model to explore carnosine biology and its therapeutic potential.

1 January 2022 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Open access
SHSelina Cannon Homaei
Selina Cannon Homaei
HBHelene Barone
Helene Barone
RKRune Kleppe
Rune Kleppe
NBNibal Betari
Nibal Betari
ARAndreas Reif
Andreas Reif
JHJan Haavik
Jan Haavik
Neurometabolic diseases (NMDs) are typically caused by genetic abnormalities affecting enzyme functions, which in turn interfere with normal development and activity of the nervous system. Although the individual disorders are rare, NMDs are collectively relatively common and often lead to lifelong difficulties and high societal costs. Neuropsychiatric manifestations, including ADHD symptoms, are prominent in many NMDs, also when the primary biochemical defect originates in cells and tissues outside the nervous system. ADHD symptoms have been described in phenylketonuria, tyrosinemias, alkaptonuria, succinic semialdehyde dehydrogenase deficiency, X-linked ichthyosis, maple syrup urine disease, and several mitochondrial disorders, but are probably present in many other NMDs and may pose diagnostic and therapeutic challenges. Here we review current literature linking NMDs with ADHD symptoms. We cite emerging evidence that many NMDs converge on common neurochemical mechanisms that interfere with monoamine neurotransmitter synthesis, transport, metabolism, or receptor functions, mechanisms that are also considered central in ADHD pathophysiology and treatment. Finally, we discuss the therapeutic implications of these findings and propose a path forward to increase our understanding of these relationships.

14 July 2015 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Open access
PDF file
KJKaya K. Jacobsen
Kaya K. Jacobsen
RKRune Kleppe
Rune Kleppe
SJStefan Johansson
Stefan Johansson
TZTetyana Zayats
Tetyana Zayats
JHJan Haavik
Jan Haavik
Monoamines critically modulate neurophysiological functions affected in several neuropsychiatric disorders. We therefore examined genes encoding key enzymes of catecholamine and serotonin biosynthesis (tyrosine and tryptophan hydroxylases—TH and TPH1/2) as well as their regulatory 14‐3‐3 proteins (encoded byYWHA‐genes). Previous studies have focused mainly on the individual genes, but no analysis spanning this regulatory network has been reported. We explored interactions between these genes in Norwegian patients with adult attention deficit hyperactivity disorder (aADHD), followed by gene‐complex association tests in four major neuropsychiatric conditions; childhood ADHD (cADHD), bipolar disorder, schizophrenia, and major depressive disorder. For interaction analyses, we evaluated 55 SNPs across these genes in a sample of 583 aADHD patients and 637 controls. For the gene‐complex tests, we utilized the data from large‐scale studies of The Psychiatric Genomics Consortium (PGC). The four major neuropsychiatric disorders were examined for association with each of the genes individually as well as in three complexes as follows: (1)TPH1andYWHA‐genes; (2)TH,TPH2andYWHA‐genes; and (3) all genes together. The results show suggestive epistasis betweenYWHAEand two other 14‐3‐3‐genes ‐YWHAZ, YWHAQ ‐in aADHD (nominalP‐value of 0.0005 and 0.0008, respectively). In PGC data, association betweenYWHAEand schizophrenia was noted (P = 1.00E‐05), whereas the combination ofTPH1andYWHA‐genes revealed signs of association in cADHD, schizophrenia, and bipolar disorder. In conclusion, polymorphisms in theYWHA‐genes and their targets may exert a cumulative effect in ADHD and related neuropsychiatric conditions, warranting the need for further investigation of these gene‐complexes. © 2015 The Authors.American Journal of Medical Genetics Part B: Neuropsychiatric GeneticsPublished by Wiley Periodicals, Inc.

12 November 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
GNGyrid Nygaard
Gyrid Nygaard
PSPeter D. Szigetvari
Peter D. Szigetvari
AGAnn Kari Grindheim
Ann Kari Grindheim
Peter RuoffPeter Ruoff
Peter Ruoff
AMAurora Martinez
Aurora Martinez
MFMarte Flydal
Marte Flydal
Dopa-responsive dystonia (DRD) is a rare movement disorder associated with defective dopamine synthesis. This impairment may be due to the fact of a deficiency in GTP cyclohydrolase I (GTPCHI, GCH1 gene), sepiapterin reductase (SR), tyrosine hydroxylase (TH), or 6-pyruvoyl tetrahydrobiopterin synthase (PTPS) enzyme functions. Mutations in GCH1 are most frequent, whereas fewer cases have been reported for individual SR-, PTP synthase-, and TH deficiencies. Although termed DRD, a subset of patients responds poorly to L-DOPA. As this is regularly observed in severe cases of TH deficiency (THD), there is an urgent demand for more adequate or personalized treatment options. TH is a key enzyme that catalyzes the rate-limiting step in catecholamine biosynthesis, and THD patients often present with complex and variable phenotypes, which results in frequent misdiagnosis and lack of appropriate treatment. In this expert opinion review, we focus on THD pathophysiology and ongoing efforts to develop novel therapeutics for this rare disorder. We also describe how different modeling approaches can be used to improve genotype to phenotype predictions and to develop in silico testing of treatment strategies. We further discuss the current status of mathematical modeling of catecholamine synthesis and how such models can be used together with biochemical data to improve treatment of DRD patients.

20 October 2023 in Neurochemistry International
Verified
Journal Article
Open access
PSPeter D. Szigetvari
Peter D. Szigetvari
SPSudarshan Shantinath Patil
Sudarshan Shantinath Patil
EBEven Birkeland
Even Birkeland
RKRune Kleppe
Rune Kleppe
JHJan Haavik
Jan Haavik
Phenylketonuria (PKU) is an autosomal recessive metabolic disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene, resulting in phenylalanine accumulation and impaired tyrosine production. In Tyrosinemia type 1 (TYRSN1) mutations affect fumarylacetoacetate hydrolase, leading to accumulation of toxic intermediates of tyrosine catabolism. Treatment of TYRSN1 with nitisinone results in extreme tissue levels of tyrosine. Although PKU and TYRSN1 have opposite effects on tyrosine levels, both conditions have been associated with neuro-psychiatric symptoms typically present in ADHD, possibly indicating an impaired dopamine (DA) synthesis. However, concrete in vivo data on the possible molecular basis for disrupted DA production under disease mimicking conditions have been lacking. In pursuit to uncover associated molecular mechanisms, we exposed an established, DA producing cell line (PC12) to different concentrations of phenylalanine and tyrosine in culture media. We measured the effects on viability, proteomic composition, tyrosine, DA and tyrosine hydroxylase (TH) levels and TH phosphorylation. TH catalyzes the rate-limiting step in DA synthesis. High extracellular levels of phenylalanine depleted cells of intracellular tyrosine and DA. Compared to physiological levels (75 μM), either low (35 μM) or high concentrations of tyrosine (275 or 835 μM) decreased cellular DA, TH protein, and its phosphorylation levels. Using deep proteomic analysis, we identified multiple proteins, biological processes and pathways that were altered, including enzymes and transporters involved in amino acid metabolism. Using this information and published data, we developed a mathematical model to predict how extracellular levels of aromatic amino acids can affect the cellular synthesis of DA via different mechanisms. Together, these data provide new information about the normal regulation of neurotransmitter synthesis and how this may be altered in neurometabolic disorders, such as PKU and TYRSN1, with implications for the treatment of cognitive symptoms resulting from comorbid neurodevelopmental disorders.

29 January 2016 in Amino Acids
Verified
Journal Article
Open access
PDF file
SGSadaf Ghorbani
Sadaf Ghorbani
AFAgnete Fossbakk
Agnete Fossbakk
AJAna Jorge-Finnigan
Ana Jorge-Finnigan
MFMarte Flydal
Marte Flydal
JHJan Haavik
Jan Haavik
RKRune Kleppe
Rune Kleppe
Tyrosine hydroxylase (TH) is regulated by members of the 14-3-3 protein family. However, knowledge about the variation between 14-3-3 proteins in their regulation of TH is still limited. We examined the binding, effects on activation and dephosphorylation kinetics of tyrosine hydroxylase (TH) by abundant midbrain 14-3-3 proteins (β, η, ζ, γ and ε) of different dimer composition. All 14-3-3 homodimers and their respective 14-3-3ε-heterodimers bound with similar high affinity (K d values of 1.4–3.8 nM) to serine19 phosphorylated human TH (TH-pS19). We similarly observed a consistent activation of bovine (3.3- to 4.4-fold) and human TH-pS19 (1.3–1.6 fold) across all the different 14-3-3 dimer species, with homodimeric 14-3-3γ being the strongest activator. Both hetero- and homodimers of 14-3-3 strongly inhibited dephosphorylation of TH-pS19, and we speculate if this is an important homeostatic mechanism of 14-3-3 target-protein regulation in vivo. We conclude that TH is a robust interaction partner of different 14-3-3 dimer types with moderate variability between the 14-3-3 dimers on their regulation of TH.